vs
Side-by-side financial comparison of Canaan Inc. (CAN) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Canaan Inc. is the larger business by last-quarter revenue ($20.8M vs $13.7M, roughly 1.5× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -18.4%, a 94.1% gap on every dollar of revenue.
Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
CAN vs XLO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.8M | $13.7M |
| Net Profit | $-3.8M | $10.4M |
| Gross Margin | 99.9% | — |
| Operating Margin | -15.9% | -86.5% |
| Net Margin | -18.4% | 75.7% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 179.1% |
| EPS (diluted) | $-0.05 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.8M | $13.7M | ||
| Q3 25 | $13.8M | $19.1M | ||
| Q2 25 | $11.4M | $8.1M | ||
| Q1 25 | — | $2.9M | ||
| Q3 24 | $10.2M | — | ||
| Q2 24 | $4.8M | — |
| Q4 25 | $-3.8M | $10.4M | ||
| Q3 25 | $-1.5M | $-16.3M | ||
| Q2 25 | $-11.9M | $-15.8M | ||
| Q1 25 | — | $-13.3M | ||
| Q3 24 | $-10.4M | — | ||
| Q2 24 | $-5.4M | — |
| Q4 25 | 99.9% | — | ||
| Q3 25 | 99.9% | — | ||
| Q2 25 | 99.9% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | 99.9% | — | ||
| Q2 24 | 99.8% | — |
| Q4 25 | -15.9% | -86.5% | ||
| Q3 25 | -27.0% | -10.1% | ||
| Q2 25 | -45.5% | -177.7% | ||
| Q1 25 | — | -472.7% | ||
| Q3 24 | -77.2% | — | ||
| Q2 24 | -193.9% | — |
| Q4 25 | -18.4% | 75.7% | ||
| Q3 25 | -11.0% | -85.4% | ||
| Q2 25 | -104.4% | -196.0% | ||
| Q1 25 | — | -452.7% | ||
| Q3 24 | -102.7% | — | ||
| Q2 24 | -112.3% | — |
| Q4 25 | $-0.05 | $-3.74 | ||
| Q3 25 | $-0.02 | $-0.11 | ||
| Q2 25 | $-0.25 | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | $6.2M | — |
| Stockholders' EquityBook value | $52.4M | $35.3M |
| Total Assets | $92.5M | $154.7M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $103.8M | ||
| Q2 25 | — | $121.6M | ||
| Q1 25 | — | $89.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | $6.2M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $6.2M | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | $52.4M | $35.3M | ||
| Q3 25 | $44.7M | $-8.1M | ||
| Q2 25 | $33.8M | $7.1M | ||
| Q1 25 | — | $10.7M | ||
| Q3 24 | $43.6M | — | ||
| Q2 24 | $56.8M | — |
| Q4 25 | $92.5M | $154.7M | ||
| Q3 25 | $81.7M | $133.7M | ||
| Q2 25 | $78.0M | $133.8M | ||
| Q1 25 | — | $103.7M | ||
| Q3 24 | $69.3M | — | ||
| Q2 24 | $73.7M | — |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-17.5M | ||
| Q2 25 | — | $-14.5M | ||
| Q1 25 | — | $29.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
